1. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Issue 8 (2nd July 2020) Authors: Weisel, Katja; Dimopoulos, Meletios; Moreau, Philippe; Yagci, Munci; Larocca, Alessandra; Kanate, Abraham S.; Vural, Filiz; Cascavilla, Nicola; Basu, Supratik; Johnson, Peter; Byeff, Peter; Hus, Marek; Rodríguez-Otero, Paula; Muelduer, Ercan; Anttila, Pekka; Hayden, Patrick J.; Krauth, Maria-Ther... Journal: Leukemia & lymphoma Issue: Volume 61:Issue 8(2020) Page Start: 1850 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗